Literature DB >> 10697062

Trends in the prescribing of psychotropic medications to preschoolers.

J M Zito1, D J Safer, S dosReis, J F Gardner, M Boles, F Lynch.   

Abstract

CONTEXT: Recent reports on the use of psychotropic medications for preschool-aged children with behavioral and emotional disorders warrant further examination of trends in the type and extent of drug therapy and sociodemographic correlates.
OBJECTIVES: To determine the prevalence of psychotropic medication use in preschool-aged youths and to show utilization trends across a 5-year span.
DESIGN: Ambulatory care prescription records from 2 state Medicaid programs and a salaried group-model health maintenance organization (HMO) were used to perform a population-based analysis of three 1-year cross-sectional data sets (for the years 1991, 1993, and 1995). SETTING AND PARTICIPANTS: From 1991 to 1995, the number of enrollees aged 2 through 4 years in a Midwestern state Medicaid (MWM) program ranged from 146,369 to 158,060; in a mid-Atlantic state Medicaid (MAM) program, from 34,842 to 54,237; and in an HMO setting in the Northwest, from 19,107 to 19,322. MAIN OUTCOME MEASURES: Total, age-specific, and gender-specific utilization prevalences per 1000 enrollees for 3 major psychotropic drug classes (stimulants, antidepressants, and neuroleptics) and 2 leading psychotherapeutic medications (methylphenidate and clonidine); rates of increased use of these drugs from 1991 to 1995, compared across the 3 sites.
RESULTS: The 1995 rank order of total prevalence in preschoolers (per 1000) in the MWM program was: stimulants (12.3), 90% of which represents methylphenidate (11.1); antidepressants (3.2); clonidine (2.3); and neuroleptics (0.9). A similar rank order was observed for the MAM program, while the HMO had nearly 3 times more clonidine than antidepressant use (1.9 vs 0.7). Sizable increases in prevalence were noted between 1991 and 1995 across the 3 sites for clonidine, stimulants, and antidepressants, while neuroleptic use increased only slightly. Methylphenidate prevalence in 2- through 4-year-olds increased at each site: MWM, 3-fold; MAM, 1.7-fold; and HMO, 3.1-fold. Decreases occurred in the relative proportions of previously dominant psychotherapeutic agents in the stimulant and antidepressant classes, while increases occurred for newer, less established agents.
CONCLUSIONS: In all 3 data sources, psychotropic medications prescribed for preschoolers increased dramatically between 1991 and 1995. The predominance of medications with off-label (unlabeled) indications calls for prospective community-based, multidimensional outcome studies.

Entities:  

Keywords:  Empirical Approach; Medicaid; Mental Health Therapies; Professional Patient Relationship

Mesh:

Substances:

Year:  2000        PMID: 10697062     DOI: 10.1001/jama.283.8.1025

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  157 in total

1.  Evidence and belief in ADHD.

Authors:  M Zwi; P Ramchandani; C Joughin
Journal:  BMJ       Date:  2000-10-21

2.  Mental health services for youths in foster care and disabled youths.

Authors:  S dosReis; J M Zito; D J Safer; K L Soeken
Journal:  Am J Public Health       Date:  2001-07       Impact factor: 9.308

3.  The limits of psychiatry.

Authors:  Duncan Double
Journal:  BMJ       Date:  2002-04-13

4.  Medical and nonmedical stimulant use among adolescents: from sanctioned to unsanctioned use.

Authors:  C Poulin
Journal:  CMAJ       Date:  2001-10-16       Impact factor: 8.262

5.  Off label prescribing in children.

Authors:  William Banner
Journal:  BMJ       Date:  2002-06-01

Review 6.  Turn-of-the-century ethical issues in child psychiatric research.

Authors:  L E Arnold
Journal:  Curr Psychiatry Rep       Date:  2001-04       Impact factor: 5.285

Review 7.  Antidepressant treatment in children and adolescents: bridging the gap between efficacy and effectiveness.

Authors:  J M Zito; D J Safer
Journal:  Curr Psychiatry Rep       Date:  2001-04       Impact factor: 5.285

8.  A critique of the international consensus statement on ADHD.

Authors:  Sami Timimi; Joanna Moncrieff; Jon Jureidini; Jonathan Leo; David Cohen; Charles Whitfield; Duncan Double; Jonathan Bindman; Henry Andrews; Eia Asen; Pat Bracken; Barry Duncan; Michaele Dunlap; Galves Albert; Michael Green; Tom Greening; Janice Hill; Rhodri Huws; Bertram Karon; Brian Kean; Michael McCubbin; Begum Miatra; Loren Mosher; Sue Parry; S DuBose Ravenel; Dominick Riccio; Richard Shulman; Jeanne Stolzer; Phil Thomas; Graham Vimpani; Al Wadsworth; Dave Walker; Norbert Wetzel; Rupert White
Journal:  Clin Child Fam Psychol Rev       Date:  2004-03

Review 9.  Areas for future investment in the field of ADHD: preschoolers and clinical networks.

Authors:  Manfred Döpfner; Aribert Rothenberger; Edmund Sonuga-Barke
Journal:  Eur Child Adolesc Psychiatry       Date:  2004       Impact factor: 4.785

10.  Pharmacologic intervention for attention-deficit hyperactivity disorder in preschoolers : is it justified?

Authors:  Jaswinder K Ghuman; Harinder S Ghuman
Journal:  Paediatr Drugs       Date:  2013-02       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.